Flurandrenolide film formulation

Claim 2

The process of treating a lesion of a persistent dermatosis treatable by an anti-inflammatory steroid which comprises applying to a skin area of a human in which there is such a lesion, a formulation capable of forming a medicated water-soluble, adherent film containing the following ingredients in the percentages (w/w) given: ______________________________________ Ingredient Percent ______________________________________ Flurandrenolide 0.01-0.5 Polyvinyl Alcohol 4-15 Polyvinylpyrrolidone 5-20 Glycerin 0-20 Ethyl Alcohol 0-30 Propylene Glycol 0-20 Benzyl Alcohol 0-5 Disodium Edetate 0-0.5 Citric Acid 0-1 Water q.s. to 100 ______________________________________ allowing the volatile constituents of the formulation to evaporate leaving a continuous adherent medicated film covering the lesion, and removing the film by peeling or with water after a period of at least 16 hours.

Claim 3

The process of treating a lesion of a persistent dermatosis treatable by an anti-inflammatory steroid which comprises applying to a skin area of a human in which there is such a lesion, a formulation capable of forming a medicated water-soluble, adherent film containing the following ingredients in the percentages (w/w) given: ______________________________________ Weight in Ingredient Grams/100 g. of Formulation ______________________________________ Flurandrenolide 0.1 Polyvinyl Alcohol 9.0 Polyvinylpyrrolidone 11.0 Glycerin 9.0 Ethyl Alcohol 10.0 Benzyl Alcohol 2.0 Propylene Glycol 3.0 Disodium Edetate 0.02 Citric Acid 0.0 Water q.s. to 100.0 ______________________________________ allowing the volatile constituents of the formulation to evaporate leaving a continuous adherent medicated film covering the lesion, and removing the film by peeling or with water after a period of at least 16 hours.

Claim 4

The process of treating a lesion of a persistent dermatosis treatable by an anti-inflammatory steroid which comprises applying to a skin area of a human in which there is such a lesion, a formulation capable of forming a medicated water-soluble, adherent film containing the following ingredients in the percentages (w/w) given: ______________________________________ Weight in Ingredient Grams/100 g. of Formulation ______________________________________ Flurandrenolide 0.1 Polyvinyl Alcohol 9.0 Polyvinylpyrrolidone 11.0 Glycerin 9.0 Ethyl Alcohol 10.0 Benzyl Alcohol 2.0 Propylene Glycol 3.0 Disodium Edetate 0.02 Citric Acid 0.0 Water q.s. to 100.0 ______________________________________ allowing the volatile constituents of the formulation to evaporate leaving a continuous adherent medicated film covering the lesion, and removing the film by peeling or with water after a period of at least 16 hours.